Zur Rose Group AG
/ Key word(s): Personnel
Zur Rose Group nominates Rongrong Hu as director
The Board of Directors will have a further female member as a result of the nomination of Rongrong Hu, and following the previously announced departures of Dr. Thomas Schneider and Prof. Dr. Volker Amelung at the next General Meeting of Shareholders it will shrink from seven to six members. With the election of Rongrong Hu, the Board's announced target of achieving at least 30 per cent female members by 2023 will be reached a year ahead of schedule.
Investors and analyst contact
Zur Rose Group
With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It also excels in continuous development of digital healthcare services and as a platform technology provider. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with focus on building up its European healthcare ecosystem networking qualified providers of products, services and digital solutions. Zur Rose's contribution will be to bring these offerings to customers and patients, pursuing its vision of creating a world where people can manage their own health in one click.
The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit zurrosegroup.com.
End of Media Release
|Company:||Zur Rose Group AG|
|Phone:||+41 52 724 08 14|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1265677|
|End of News||EQS News Service|